MaxCyte Appoints New CFO, Shares Rise 1.69%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy MXCT?
Source: seekingalpha
- New CFO Appointment: MaxCyte announced the appointment of Parmeet Ahuja as CFO, effective March 30, 2026, succeeding Douglas Swirsky, who is stepping down as previously announced; Ahuja brings over 20 years of finance leadership experience, most recently serving as vice president of investor relations at Agilent Technologies.
- Positive Stock Reaction: Following the announcement, MaxCyte's shares rose by 1.69%, indicating market confidence in the new CFO and expectations for improved financial management going forward.
- Financial Outlook: MaxCyte anticipates fourth-quarter core revenue between $6.6 million and $6.7 million, reflecting the company's ongoing growth potential in the biotechnology sector despite facing intensified industry competition.
- Market Dynamics: Within MaxCyte's financial landscape, AAR and Noah Holdings are viewed as strong buys, while Blaize and Fractyl Health lag behind, highlighting the varying investment sentiments across different companies in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MXCT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MXCT
Wall Street analysts forecast MXCT stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.740
Low
4.94
Averages
6.92
High
8.89
Current: 0.740
Low
4.94
Averages
6.92
High
8.89
About MXCT
MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MAXCYTE INC REPORTS Q4 2025 TOTAL REVENUE OF $7.3 MILLION IN SEC FILING
- Company Overview: MAXCYT, Inc. reported a total revenue of $7.3 million for the fourth quarter of 2025.
- Financial Filing: The revenue figures were disclosed in a recent SEC filing.
See More
MaxCyte Q4 2025 Earnings Call Insights
- Revenue Decline: MaxCyte reported total revenue of $33 million for 2025, a 15% decrease from $38.6 million in 2024, with core revenue at $29.6 million, indicating significant challenges and revenue pressure in the market.
- New Product Launch: The company launched the ExPERT DTx platform aimed at accelerating early-stage research and drug discovery, despite facing a $4 million revenue headwind from customer program consolidation, with 2026 total revenue guidance set between $30 million and $32 million.
- Management Changes: Parmeet Ahuja will succeed Doug Swirsky as Chief Financial Officer effective March 30, reflecting strategic adjustments in the executive team to address current market challenges.
- Cash Position: As of the end of 2025, MaxCyte had total cash and cash equivalents and investments of $155.6 million with no debt, demonstrating financial stability that supports future growth initiatives.
See More
MaxCyte Reports 2025 Revenue Decline Amid Strategic Developments
- Revenue Decline: MaxCyte's total revenue for 2025 was $33 million, reflecting a 15% decline from 2024, indicating financial challenges primarily due to customer program consolidations, with expectations of continued core revenue decline in 2026.
- Core Revenue Drop: The core revenue for 2025 stood at $29.6 million, a 9% decrease year-over-year, with Q4 core revenue at $6.8 million, down 22% from Q4 2024, highlighting competitive pressures in the market.
- High Gross Margin: Despite the revenue decline, MaxCyte achieved a gross margin of 78% in Q4 2025, up from 74% in Q4 2024, demonstrating effective cost management strategies that could support future profitability.
- Financial Flexibility: By the end of 2025, MaxCyte maintained $155.6 million in cash with no debt, providing financial flexibility that supports future strategic investments and business development initiatives.
See More
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript
See More
MaxCyte Q4 Earnings Miss Expectations
- Disappointing Earnings: MaxCyte reported a Q4 GAAP EPS of -$0.09, missing expectations by $0.01, indicating challenges in profitability that may affect investor confidence.
- Revenue Decline: The company’s Q4 revenue of $7.3 million represents a 16.1% year-over-year decline, falling short by $1.86 million, reflecting pressures from weak market demand and increased competition.
- Full-Year Revenue Guidance: MaxCyte expects full-year revenue to range between $30 million and $32 million, with core revenue projected at $25 million to $27 million and SPL program-related revenue around $5 million, indicating ongoing investment in specific areas.
- Milestone Payments and Royalties: The SPL program-related revenue guidance includes approximately $3 million from milestone payments and about $2 million from commercial royalties, highlighting the company’s strategic focus on new product development and market penetration.
See More
MAXCYTE INC PROJECTS CORE REVENUE BETWEEN $25 MILLION AND $27 MILLION FOR 2026
Revenue Projection: The core revenue for MAXCYT is projected to increase from $25 million to $27 million by 2026.
Financial Outlook: This outlook indicates a positive growth trend for the company in the coming years.
See More
MAXCYTE INC REPORTS Q4 2025 TOTAL REVENUE OF $7.3 MILLION IN SEC FILING
- Company Overview: MAXCYT, Inc. reported a total revenue of $7.3 million for the fourth quarter of 2025.
- Financial Filing: The revenue figures were disclosed in a recent SEC filing.
See More
MaxCyte Q4 2025 Earnings Call Insights
- Revenue Decline: MaxCyte reported total revenue of $33 million for 2025, a 15% decrease from $38.6 million in 2024, with core revenue at $29.6 million, indicating significant challenges and revenue pressure in the market.
- New Product Launch: The company launched the ExPERT DTx platform aimed at accelerating early-stage research and drug discovery, despite facing a $4 million revenue headwind from customer program consolidation, with 2026 total revenue guidance set between $30 million and $32 million.
- Management Changes: Parmeet Ahuja will succeed Doug Swirsky as Chief Financial Officer effective March 30, reflecting strategic adjustments in the executive team to address current market challenges.
- Cash Position: As of the end of 2025, MaxCyte had total cash and cash equivalents and investments of $155.6 million with no debt, demonstrating financial stability that supports future growth initiatives.
See More
MaxCyte Reports 2025 Revenue Decline Amid Strategic Developments
- Revenue Decline: MaxCyte's total revenue for 2025 was $33 million, reflecting a 15% decline from 2024, indicating financial challenges primarily due to customer program consolidations, with expectations of continued core revenue decline in 2026.
- Core Revenue Drop: The core revenue for 2025 stood at $29.6 million, a 9% decrease year-over-year, with Q4 core revenue at $6.8 million, down 22% from Q4 2024, highlighting competitive pressures in the market.
- High Gross Margin: Despite the revenue decline, MaxCyte achieved a gross margin of 78% in Q4 2025, up from 74% in Q4 2024, demonstrating effective cost management strategies that could support future profitability.
- Financial Flexibility: By the end of 2025, MaxCyte maintained $155.6 million in cash with no debt, providing financial flexibility that supports future strategic investments and business development initiatives.
See More
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript
See More
MaxCyte Q4 Earnings Miss Expectations
- Disappointing Earnings: MaxCyte reported a Q4 GAAP EPS of -$0.09, missing expectations by $0.01, indicating challenges in profitability that may affect investor confidence.
- Revenue Decline: The company’s Q4 revenue of $7.3 million represents a 16.1% year-over-year decline, falling short by $1.86 million, reflecting pressures from weak market demand and increased competition.
- Full-Year Revenue Guidance: MaxCyte expects full-year revenue to range between $30 million and $32 million, with core revenue projected at $25 million to $27 million and SPL program-related revenue around $5 million, indicating ongoing investment in specific areas.
- Milestone Payments and Royalties: The SPL program-related revenue guidance includes approximately $3 million from milestone payments and about $2 million from commercial royalties, highlighting the company’s strategic focus on new product development and market penetration.
See More
MAXCYTE INC PROJECTS CORE REVENUE BETWEEN $25 MILLION AND $27 MILLION FOR 2026
Revenue Projection: The core revenue for MAXCYT is projected to increase from $25 million to $27 million by 2026.
Financial Outlook: This outlook indicates a positive growth trend for the company in the coming years.
See More
